Mark Brader

Mark Brader is a seasoned scientist with extensive experience in biopharmaceutical development, particularly in mRNA science and protein characterization. Currently serving as a Research Fellow at Moderna since May 2016, Mark Brader focuses on transformative medicines utilizing mRNA technology. Prior roles include Honorary Professor at The University of Auckland and Principal Scientist at Biogen, where Mark Brader led formulation development teams and mentored emerging scientists. Additional experience includes positions at Novo Nordisk, providing expertise in monoclonal antibodies, and Eli Lilly and Company, where Mark Brader established a biophysical characterization group. Mark Brader holds a PhD in Chemistry from Massey University, complemented by postdoctoral fellowships in Inorganic Chemistry and Biochemistry at Rutgers University and University of California, Riverside, respectively.